Colorectal cancer in Chinese patients: current and emerging treatment options

Li, Leung; B.Y., Brigette

doi:10.2147/ott.s48409

Cited by 26 publications

(19 citation statements)

References 117 publications

(100 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of sequencing showed no mutation in the V600E region of BRAF . This finding was similar to that reported in several studies in Iran and some Asian countries 17,37…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran

Dolatkhah

Somi

Kermani

et al. 2016

OTT

View full text Add to dashboard Cite

BackgroundColorectal cancer (CRC) is the third-most common cancer in Iran. The increasing incidence of CRC in the past three decades has made it a major public health burden in the country. This study aimed to determine any relationship of specific mutations in CRCs with clinicopathologic aspects and outcome of patients.Materials and methodsThis study was conducted on 100 CRC patients by the case-only method. Polymerase chain-reaction products were analyzed by Sanger sequencing, and sequence results were compared with the significant KRAS and BRAF gene mutations in the My Cancer Genome database. Logistic regression models were used to detect associations of clinicopathologic characteristics with each of the mutations. Kaplan–Meier and Cox regression models were constructed to estimate overall survival in patients.ResultsA total of 26 subjects (26%) had heterozygote-mutant KRAS, and mutations were not detected in the amplified exon of BRAF in both tumor and normal tissues of the 100 CRCs. Rectal tumors had 1.53-fold higher likelihood of KRAS mutations than colon tumors, and men had 1.37-fold higher odds than women. The presence of metastasis increased the likelihood of KRAS mutations 2.36-fold over those with nonmetastatic CRCs. Compared to patients with KRAS wild-type cancers, those with KRAS mutations had significantly higher mortality (hazard ratio 3.74, 95% confidence interval 1.44–9.68; log-rank P=0.003).ConclusionBetter understanding of the causality of CRC can be established by combining epidemiology and research on molecular mechanisms of the disease.

show abstract

“…The results of sequencing showed no mutation in the V600E region of BRAF . This finding was similar to that reported in several studies in Iran and some Asian countries 17,37…”

Section: Discussionsupporting

confidence: 92%

“…The highest frequency is reported in the US and Australia, with 9.5%–12.5% of patients with CRC showing this mutation 36. Furthermore, 4.2%–4.4% of patients carry mutant genes 37. A study by Brim et al showed that the frequency of this mutation was very low in Eastern countries 38.…”

Section: Discussionmentioning

confidence: 99%

Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran

Dolatkhah

Somi

Kermani

et al. 2016

OTT

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) is one of the most common types of malignancy worldwide, with an increasing incidence in China ( 1 ). In addition, it is the fourth leading cause of cancer-associated mortality, and is responsible for 529,000 cases of mortality per year worldwide ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

The clinical significance of forkhead box protein A1 and its role in colorectal cancer

Jiang

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Forkhead box protein A1 (FOXA1) is a transcription factor; recent studies have reported that FOXA1 has an oncogenic or tumor suppressive role in human malignancies, and its expression is associated with the prognosis of patients with cancer. However, further studies are required to determine the clinical significance of FOXA1 and its role in colorectal cancer (CRC). In the present study, FOXA1 expression was detected in 90 samples of CRC tissues and matched noncancerous tissues using immunohistochemistry. In these cases, FOXA1 expression was detected in 57.8% (52/90) of the CRC samples, whereas only 37.8% (34/90) of the noncancerous specimens exhibited a positive FOXA1 signal. In addition, the present study demonstrated that the mRNA expression levels of FOXA1 were significantly increased in CRC tissues compared with in matched tumor-adjacent tissues. Furthermore, the positive expression of FOXA1 was associated with poor clinicopathological characteristics of CRC, including poor tumor differentiation, large tumor size, lymph node metastases and advanced tumor-node-metastasis tumor stage. Notably, patients with CRC with positive FOXA1 expression exhibited a significantly reduced 5-year survival rate compared with those with negative FOXA1 expression. Multivariate Cox regression analysis revealed that FOXA1 expression was an independent prognostic indicator for patients with CRC. In addition, FOXA1 knockdown evidently inhibited cell proliferation and induced apoptosis in SW480 and HCT116 CRC cells. Notably, FOXA1 knockdown also prominently reduced the expression of yes-associated protein (YAP) in SW480 and HCT116 cells. In conclusion, the results of the present study indicated that FOXA1 may be considered a potential prognostic marker, and may promote tumor growth of CRC by upregulating YAP expression.

show abstract

“…Colon cancer has become the third leading cause of tumor-related deaths in the world 1 , and its incidence is rapidly rising in Chinese cities along with economic development 2 . Colon cancer normally develops through a multistep process that results from the progressive accumulation of mutations and epigenetic alterations in tumor suppressor genes and oncogenes, which include both DNA hypermethylation and chromatin modifications such as histone methylation and deacetylation 3 .…”

Section: Introductionmentioning

confidence: 99%

DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis

Sha

Mao

Wang

et al. 2015

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

EZH2 is over-expressed in human colon cancer and is closely associated with tumor proliferation, metastasis and poor prognosis. Targeting and inhibiting EZH2 may be an effective therapeutic strategy for colon cancer. 3-Deazaneplanocin A (DZNep), as an EZH2 inhibitor, can suppress cancer cell growth. However, the anti-cancer role of DZNep in colon cancer cells has been rarely studied. In this study, we demonstrate that DZNep can inhibit the growth and survival of colon cancer HCT116 cells by inducing cellular senescence and apoptosis. The study provides a novel view of anti-cancer mechanisms of DZNep in human colon cancer cells.

show abstract

Colorectal cancer in Chinese patients: current and emerging treatment options

Cited by 26 publications

References 117 publications

Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran

Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran

The clinical significance of forkhead box protein A1 and its role in colorectal cancer

DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis

Contact Info

Product

Resources

About